Ledipasvir, sofosbuvir; 33.75mg/150mg, 45mg/200mg. <3yrs: not established. Test for HBV infection prior to initiation. ≥3yrs (<17kg): 33.75mg/150mg (pellets) once ...

Giving Harvoni to patients with the more aggressive genotype 3 strain of the disease who have cirrhosis and previous drug treatment would cost a much bigger £105,761, according to NICE.

The draft decision covers BMS' Daklinka (daclatasvir), Gilead's Harvoni (Ledipasvir-sofosbuvir) and AbbVie's Viekirax (ombitasvir-paritaprevir-ritonavir) with or without Exviera (dasabuvir).